VC: Speedel leads with $56M for Phase III



Speedel leads with $56M for Phase III

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Speedel
Basel, Switzerland

$56 million

The proceeds from this latest round will be used for clinical pipeline development, specifically for the Phase III study of SPP301.

Tengion
King of Prussia, PA

$39 million
first

Oak Investment Partners

Its lead products are organs and tissues derived from a patient's own cells that can be used to replace the patient's diseased or impaired organ or tissues.

Aureon Laboratories
Yonkers. NY

$20 million
second

Atlas Venture, Sprout Group

Aureon has been developing the Prostate Px, a predictive test that will provide urologists with insight into a patient's chance of developing a cancer recurrence following the removal of the prostate.

Intercytex
London

12M sterling

Avlar BioVentures

The financing will be used to complete Phase III trials of ICX-PRO, Intercytex' active woundcare product, take ICX-TRC, its hair regeneration product, through later stage clinical trials and to move ICX-SKN, a living skin replacement, into the clinic.

Oxford Immunotec
Oxford, UK

7M sterling
second

Prelude Ventures

The money will extend marketing of its first product, a test for tuberculosis.

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.